Company Analysis TherapeuticsMD, Inc.
1. Summary
Advantages
- The stock's return over the last year (87.64%) is higher than the sector average (-2.93%).
- Current debt level 18.48% is below 100% and has decreased over 5 years from 135.68%.
Disadvantages
- Price (1.67 $) is higher than fair price (1.39 $)
- Dividends (0%) are below the sector average (0.544%).
- The company's current efficiency (ROE=-7.7%) is lower than the sector average (ROE=109.03%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| TherapeuticsMD, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.8% | -13.4% | -0.6% |
| 90 days | 36.9% | -1.6% | 2.9% |
| 1 year | 87.6% | -2.9% | 21% |
TXMD vs Sector: TherapeuticsMD, Inc. has outperformed the "Healthcare" sector by 90.57% over the past year.
TXMD vs Market: TherapeuticsMD, Inc. has outperformed the market by 66.65% over the past year.
Stable price: TXMD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: TXMD with weekly volatility of 1.69% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (1.67 $) is higher than the fair price (1.39 $).
Price is higher than fair: The current price (1.67 $) is 16.8% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-5.82) is higher than that of the sector as a whole (-205.4).
P/E vs Market: The company's P/E (-5.82) is higher than that of the market as a whole (-65.33).
5.3. P/BV
P/BV vs Sector: The company's P/BV (0.434) is lower than that of the sector as a whole (245).
P/BV vs Market: The company's P/BV (0.434) is lower than that of the market as a whole (50.62).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (6.75) is lower than that of the sector as a whole (61.67).
P/S vs Market: The company's P/S indicator (6.75) is lower than that of the market as a whole (138.73).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-7.63) is lower than that of the sector as a whole (12.25).
EV/Ebitda vs Market: The company's EV/Ebitda (-7.63) is higher than that of the market as a whole (-48.34).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -19.79% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-19.79%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-609.67%).
6.4. ROE
ROE vs Sector: The company's ROE (-7.7%) is lower than that of the sector as a whole (109.03%).
ROE vs Market: The company's ROE (-7.7%) is higher than that of the market as a whole (-10.16%).
6.6. ROA
ROA vs Sector: The company's ROA (-5.31%) is lower than that of the sector as a whole (-2.42%).
ROA vs Market: The company's ROA (-5.31%) is lower than that of the market as a whole (40.05%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (8.78%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.544%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
